Quadrant Biosciences
World's First Saliva Test for Autism - Available in Clinics Now
Analytics
Raised to Date: $1,004,649
Aggregate Commitments $
Wefunder
02/02/2020
08/15/2020
$50,000
$15,000,000
$501
Equity - Common
RegA+
$266,000,000
Weekly Commitments $
08/31/2020
2,009%
7%
$5,152
976
Syracuse, New York
Healthcare & Pharmaceuticals
HealthTech
Quadrant Biosciences, with a pre-money valuation of $266 million, is raising funds on Wefunder through Reg A+ crowdfunding. The company has launched the world’s first saliva test for autism and is developing a pipeline of products, including tests for schizophrenia, anorexia nervosa, concussion, and Parkinson’s disease. The test for autism, The Clarifi ASD Test, is a game-changer in autism diagnosis and indicates the probability of a child having autism spectrum disorder. Quadrant Biosciences was founded by Richard Uhlig and has raised over $30 million in previous rounds of financing. The current round of crowdfunding has a minimum goal of $50,000 and a maximum goal of $15,000,000, and the proceeds will be used in developing more tests. Quadrant Biosciences has multiple international research partnerships and is working on developing a rapid saliva test for COVID-19.
Balance Sheet
|
Cash and Cash Equivalents |
$3,107,794 |
|
Investment Securities |
$0 |
|
Total Investments |
$0 |
|
Accounts and Notes Receivable |
$116,383 |
|
Loans |
$0 |
|
Property, Plant and Equipment (PP&E) |
$38,292 |
|
Property and Equipment |
$0 |
| Total Assets |
$9,846,764 |
|
Accounts Payable & Accrued Liabilities |
$145,712 |
|
Policy Liabilities and Accruals |
$0 |
|
Deposits |
$0 |
|
Long Term Debt |
$5,304,909 |
|
Total Liabilities |
$5,947,496 |
|
Total Stockholders' Equity |
$3,899,268 |
| Total Liabilities and Equity |
$9,846,764 |
Statement of Comprehensive Income Information
|
Total Revenues |
$343,449 |
|
Total Interest Income |
$0 |
|
Costs & Expenses Applicable to Rev |
$208,446 |
|
Total Interest Expenses |
$0 |
|
Depreciation and Amortization |
$11,331 |
| Net Income |
$-4,840,262 |
|
Earnings Per Share - Basic |
$0 |
|
Earnings Per Share - Diluted |
$0 |
Summary of Crowdfunding Raises
| Close Date | Platform | Valuation/Cap | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|
| 02/18/2021 | Wefunder | $0 | $411,608 | Convertible Note | Confirmed Closed | RegCF |
| 08/15/2020 | Wefunder | $266,000,000 | $1,004,649 | Equity - Common | Confirmed Closed | RegA+ |
Analyst Report
Ratings Platform - Beta Trial
Our new ratings and analytics platform is currently in Beta. To gain access to the Beta platform features, upgrade to a Pro paid account and accept the Beta terms on any page.
For a limited time, use coupon code "TRYMERLIN20" for a free 20 day trial of Kingscrowd Pro and Merlin Beta. Your paid subscription will activate at the end of 20 days. Cancel anytime.Other Deals
MedVector on StartEngine
The COVID-19 pandemic has grown the telehealth industry exponentially. A recent study of U.S medical specialists found that
Phoenix PharmaLabs on Netcapital
In the years before the world’s current COVID-19 crisis, America in particular faced a deadly and persistent threat…
C-Reveal Therapeutics on NetCapital
Cancer is the great, mysterious killer of medical science. As of January 2019, there were an